Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01046422 · ClinicalTrials.gov registry record · Phase 2
Safety Study of BMS-770767 in Subjects With Type 2 Diabetes
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
NCT01046422 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 76 participants.
The verdict
NCT01046422, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if BMS-770767 is safe, well tolerated, measure its levels in the blood (pharmacokinetics), and measure the levels of chemicals (biomarkers) that may be affected by this drug (pharmacodynamics) in a type 2 diabetes patient population
Interventions
- DRUG Placebo
- DRUG BMS-770767
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2010-05 |
| Est. Completion | 2011-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01046422
The ClinicalTrials.gov registry entry for NCT01046422 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01046422 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01046422 about?
NCT01046422 is a clinical study titled "Safety Study of BMS-770767 in Subjects With Type 2 Diabetes". The purpose of this study is to determine if BMS-770767 is safe, well tolerated, measure its levels in the blood (pharmacokinetics), and measure the levels of chemicals (biomarkers) that may be affected by this drug (pharmacodynamics) in a type 2 diabetes patient population
What is the current status of trial NCT01046422?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2010-05. Estimated completion is 2011-01.
What interventions are being tested in trial NCT01046422?
The interventions under investigation include: Placebo (DRUG), BMS-770767 (DRUG).
Who is sponsoring clinical trial NCT01046422?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.